Notes

1. This test is performed on plasma samples only.
2. The linear quantitation range of the assay is 12 IU/mL to 7 x 10⁸ IU/mL.
3. Results below the lower limit of quantitation indicate low-level viremia and should be interpreted along with clinical findings.
4. Results above the upper limit may require dilution and repeat testing for accurate quantification.
5. Quantitative results should always be interpreted in the context of clinical presentation, treatment status, and other laboratory findings.

Clinical Interpretation

1. A "Target Not Detected" result indicates absence of detectable HCV RNA, suggesting no active viremia at the time of testing.
2. Detection below 12 IU/mL may indicate early infection, resolving infection, or response to therapy; follow-up testing is recommended.
3. Detection within 12 IU/mL to 7 x 10⁸ IU/mL confirms active infection with quantifiable viral load.
4. HCV RNA quantification is essential for:
   • Baseline viral load assessment
   • Monitoring response to antiviral therapy
   • Evaluating virological relapse or sustained virologic response (SVR)

Intended Use

• Diagnosis and confirmation of active HCV infection
• Baseline viral load determination prior to therapy
• Monitoring response to direct-acting antiviral (DAA) therapy
• Detection of virological relapse or treatment failure

Notes

1. This test is performed on plasma samples only.
2. The assay has a quantitation range of 46.25 IU/mL to 1 x 10⁸ IU/mL.
3. Results below the quantitation limit indicate low-level viremia and should be interpreted with clinical correlation.
4. Samples above the upper limit may require dilution and repeat testing for accurate quantification.
5. Quantitative HIV-1 RNA results should always be interpreted in conjunction with clinical findings, CD4 count, and treatment status.

Clinical Interpretation

1. Detection of HIV-1 RNA indicates active viral replication.
2. Low-level viremia (<46.25 IU/mL) may be seen in:
   • Early infection
   • Patients on antiretroviral therapy (ART)
   • Transient viral "blips"
3. Quantifiable viral load (within range) is used for:
   • Baseline viral load assessment
   • Monitoring response to ART
   • Detecting treatment failure
4. Persistently high viral loads may indicate poor treatment response or drug resistance.

Intended Use

• Diagnosis and confirmation of HIV-1 infection
• Baseline viral load determination before ART initiation
• Monitoring response to antiretroviral therapy
• Detection of virological failure or rebound

Notes

1. This test is performed on plasma samples only.
2. The quantitation range of the assay is 10 IU/mL to 7 x 10⁸ IU/mL.
3. Results below 10 IU/mL indicate low-level HBV DNA presence and are not reliably quantifiable.
4. Samples above the upper limit may require dilution and repeat testing for accurate quantification.
5. Results should always be interpreted in conjunction with clinical findings, liver function tests, and serological markers (HBsAg, HBeAg, Anti-HBe).

Clinical Interpretation

1. Detection of HBV DNA indicates active viral replication.
2. Low-level detection (<10 IU/mL) may be seen in:
   • Early infection
   • Patients under antiviral therapy
   • Occult HBV infection
3. Quantifiable viral load is essential for:
   • Baseline viral load assessment
   • Monitoring response to antiviral therapy
   • Assessing disease progression and infectivity
4. Persistently high viral load may indicate active disease or poor therapeutic response.

Intended Use

• Detection and quantification of HBV DNA in plasma
• Baseline viral load determination
• Monitoring response to antiviral therapy
• Assessment of disease progression and treatment efficacy

Interpretive Data: If result is TB negative: This indicates no TB infection. However, if there is a strong history of suggestive TB a repeat test should be done If result is TB is positive and Rifampicin & Isoniazid is sensitive, that indicates TB can be treated with commonly used drugs. If result is Rifampicin and or Isoniazid resistance and patient's clinical history suggest previous TB treatment indicating drug resistance -TB that is difficult to treat with commonly used drugs. which requires specialized management of multidrug resistant TB (MDR TB). If result is Rifampicin and or Isoniazid resistance positive and you have NOT previously taken TB treatment: This may indicate multidrug resistant TB (MDR TB), which requires specialized management

Clinical Significance: MTB RIF&INH Resistance Detection kit can quickly identify possible multidrug-resistant TB (MDR TB). MDR TB is TB that is resistant to both isoniazid (INH) and Rifampicin (RIF), two of the most effective TB drugs. Rapid diagnosis of RIF resistance potentially allows TB patients to start on effective treatment. The information provided by the MTB RIF&INH Resistance Detection kit aids in selecting treatment regimens and reaching infection control decisions quickly.

Limitations: A negative result does not exclude M. tuberculosis infection. PCR-based assays are highly sensitive assays. There are several reasons for paradoxical results, which include contamination during specimen collection, selection of inappropriate specimens, aliquot phenomenon and interference by inherent inhibitors in the sample. Whole blood is not the specimen of choice in patients suspected of having pulmonary or extra pulmonary tuberculosis. The test should be performed on any uncontaminated specimen from the suspected site for which Mycobacteria are a consideration.

Interpretive Data:The Limit of Detection (LOD or analytical sensitivity):

The TripleH ID Real Time assay uses one step RT-PCR to detect all three tests using a single tube. Each of these steps incorporates an internal control to validate each reaction. TripleH ID-NAT is a multiplex assay provides simultaneous detection of HIV RNA, HBV DNA and HCV-RNA in clinical specimens, with hydrolysis probe chemistry. The target sequences for the TripleH ID test is in the highly conserved region and hence can detect all genotypes

Clinical Significance: To reduce the risk of transfusion transmitted infections (TTIs) in the recipients, thus providing an additional layer of blood safety

Limitations: PCR-based assays are highly sensitive. There are several reasons for paradoxical results, which include interference by inherent inhibitors and degradation of RNA due to pre-analytical errors. Variation in viral load values can be observed due to non-adherence to specimen collection protocol. Hence collection must be in EDTA vacutainer and the plasma separated and frozen immediately.

Interpretive Data: {{ sample_result }}